Search
43 studies match these filters. Showing 26–43 of 43 studies
| Registration number | Study | Status | Phase | Enrolment | Sites / countries | Start year | Last updated | Actions |
|---|---|---|---|---|---|---|---|---|
| NCT07610278 | A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia This is a multicenter, randomized, double-blind, factorial design Phase 2 study to evaluate the pharmacodynamics, safety and tolerability of a combination of QCZ484 and inclisiran compared to QCZ484, inclisiran, and placebo in participants with hypertension and concomitant hypercholesterolemia. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 29 sites in total · contact listed | Recruiting | Phase 2 | 120target | 29 / 1 | 2026 | Jul 30, 2026 | |
| NCT07037459 | Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fract… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 686 sites in total | Recruiting | Phase 3 | 5,056target | 686 / 35 | 2025 | Oct 29, 2026 | |
| NCT06215716 | A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 361 sites in total | Recruiting | Phase 3 | 1,650target | 361 / 18 | 2023 | Nov 6, 2026 | |
| NCT04852887 | De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 832 sites in total · contact listed | Recruiting | Phase 3 | 1,670target | 832 / 4 | 2021 | Apr 23, 2026 | |
| NCT06937177 | Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy This is a randomized, double-blind, placebo-controlled basket trial evaluating mifomelatide (TCMCB07) administered daily by subcutaneous (SC) injection in up to 120 patients. Patients will be enrolled into two cohorts 1) patients with newly diagnosed, advanced, unresectable colorectal cancer (CRC) o… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 26 sites in total · contact listed | Recruiting | Phase 2 | 120target | 26 / 2 | 2025 | Jul 15, 2026 | |
| NCT07064473 | EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empaglifl… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 1,142 sites in total · contact listed | Recruiting | Phase 3 | 11,800target | 1,142 / 51 | 2025 | Nov 12, 2026 | |
| NCT05485961 | Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo. Part 2: Phase 3 aims to assess the efficacy of CSL300 vs placebo on cardiovascular (CV) out… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 566 sites in total · contact listed | Recruiting | Phase 2 / Phase 3 | 3,110target | 566 / 35 | 2024 | Sep 21, 2026 | |
| NCT07190300 | TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) The purpose of this study is to evaluate the safety, tolerability, and efficacy of two different treatment combinations of tulmimetostat in participants with de novo or recurrent metastatic hormone-sensitive prostate cancer (mHSPC). Phase I aims to determine the recommended dose(s) for expansion (RD… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 31 sites in total · contact listed | Recruiting | Phase 1 / Phase 2 | 181target | 31 / 14 | 2026 | Nov 13, 2026 | |
| NCT03723928 | S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as t… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 723 sites in total | Recruiting | Not applicable | 739target | 723 / 3 | 2018 | Nov 9, 2026 | |
| NCT06909565 | Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin th… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 153 sites in total · contact listed | Recruiting | Phase 4 | 6,000target | 153 / 1 | 2025 | Nov 16, 2026 | |
| NCT04553770 | Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer This phase II trial investigates how well trastuzumab deruxtecan works alone or in combination with anastrozole in treating patients with HER2 low, hormone receptor positive breast cancer. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called derux… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 9 sites in total · contact listed | Recruiting | Phase 2 | 88target | 9 / 1 | 2020 | Nov 10, 2025 | |
| NCT07225946 | A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or death due to any cause) when compared to treatment with docetaxe… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 165 sites in total | Recruiting | Phase 3 | 800target | 165 / 17 | 2025 | Nov 3, 2026 | |
| NCT06982521 | Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 254 sites in total | Recruiting | Phase 3 | 540target | 254 / 27 | 2025 | Nov 5, 2026 | |
| NCT07453069 | Effect of FB301 on Vaginal Bacterial Profile in Women With Asymptomatic Vaginal Dysbiosis Undergoing a Mock Frozen Embryo Transfer Cycle The goal of this clinical trial is to evaluate FB301 during a mock frozen embryo transfer (FET) cycle in pre-menopausal women aged 18 to 45 years with a prior failed FET and a defined vaginal bacterial imbalance (dysbiosis). The main question it aims to answer is: • Does treatment with FB301 durin… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 4 sites in total · contact listed | Recruiting | Phase 2 | 30target | 4 / 1 | 2026 | Oct 15, 2026 | |
| NCT04729114 | A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with advanced prostate cancer can take part in this study. Their canc… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 25 sites in total | Recruiting | Phase 1 | 174target | 25 / 2 | 2021 | Feb 4, 2026 | |
| NCT02402244 | Project: Every Child for Younger Patients With Cancer This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 279 sites in total · contact listed | Recruiting | 75,000target | 279 / 6 | 2015 | Nov 19, 2026 | ||
| NCT06906562 | A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has spread from where it first started to other places in the body… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 109 sites in total · contact listed | Recruiting | Phase 2 | 40target | 109 / 1 | 2025 | Feb 17, 2026 | |
| NCT03866382 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blo… ✓ Contact✗ Claimed Nearest site: Kingman, Kansas, United States — 28 km away · 582 sites in total | Recruiting | Phase 2 | 314target | 582 / 2 | 2019 | Nov 18, 2026 |